Advancing innovative therapies for HBV cure in people with HIV/HBV and HBV in the united states - 7. Project summary/abstract globally, approximately 300 million live with chronic HBV (CHB) and 40…

Active Grant Awarded

Award ID
R21AI198128
Recipient
Awarding agency
Obligated
$414,984

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 27% complete
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

About this award

The National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services' National Institutes of Health, awarded The Trustees of the University of Pennsylvania (doing business as University of Pennsylvania) $414,984 on May 6, 2026, under Allergy and Infectious Diseases Research (CFDA 93.855). The grant, titled "Advancing Innovative Therapies for HBV Cure in People with HIV/HBV and HBV in the United States," funds research on patient and provider perspectives on whether and how to discontinue hepatitis B treatment during clinical trials of novel curative HBV therapies, including whether discontinuation is desired, how long it lasts, and how to manage it in people with HIV/HBV coinfection. The period of performance ends April 30, 2028, and the place of performance is Philadelphia, Pennsylvania 19104.

Hepatitis B Foundation is the sub-recipient under sub-award R21AI198128-505163, dated June 17, 2026. The foundation contributes expertise in developing the in-depth interview guides and online survey, conducts community and provider interviews under Aim 1, and establishes and manages an HIV/HBV Community Advisory Board involved in all three aims. For the Aim 2 survey, it leads recruitment through its 12,000-subscriber e-newsletter, social media accounts with 70,000 followers, a 3,000-subscriber U.S. advocacy network, and email outreach to 75 HBV storytellers.

Description

Advancing innovative therapies for HBV cure in people with HIV/HBV and HBV in the united states - 7. Project summary/abstract globally, approximately 300 million live with chronic HBV (CHB) and 40 million people live with HIV. Due to shared transmission routes, approximately 10% of people with HIV (PWH) also live with HBV (PHBV). Importantly, HIV/HBV coinfection is associated with increased mortality. Like HIV, while effective HBV treatments are available, there is no cure for HBV. Hepatitis B surface antigen (HBSAG) loss, the definition of HBV functional cure, decreases incidence of hepatocellular carcinoma (HCC) and end-stage liver disease (ESLD), yet is not easily attained with current therapy. As such, the development of novel HBV therapies, aiming for HBV functional cure, is rapidly advancing. HBV functional cure research has become a scientific priority of the NIH, industry, academia, and the community with over 50 clinical trials and compounds in development. Interestingly, HBV functional cure occurs more often in PWH/PHBV, making this an ideal cohort in which to study HBV curative therapies. Despite the pace and volume of HBV cure research, there is little knowledge about patient and provider perspectives on key HBV clinical trial approaches - unlike in HIV cure research, where over a decade of experience has informed priorities. One of the key clinical trial-related questions is whether and how to implement HBV treatment discontinuations, which will be necessary to study the efficacy of curative and finite HBV novel therapies. This will pose specific challenges in PWH/PHBV, such as the heightened likelihood of rebound hepatitis and the ongoing need for HIV antiretroviral treatment (art). There is a notable lack of data regarding both patient and provider knowledge and priorities concerning this pivotal research phase, including questions of whether HBV treatment discontinuations are desired, the duration of discontinuation, or how to manage IT. Similarly, there are limited data on trial design elements such as type of novel therapies, timing of therapy initiation, and willingness to participate in HBV cure trials. These knowledge gaps remain key hurdles to advancing effective, safe, and acceptable HBV cure strategies. Data from this application will be crucial for the development of HBV clinical trials attractive to PWH/PHBV and PHBV. Our proposed work will inform outreach, recruitment, consent, and retention of participants in future HBV clinical trials. To this end, our specific aims are as follows: aim 1 will explore priorities of PWH/PHBV, PHBV and providers around key aspects of HBV clinical trials including HBV treatment discontinuations, choice of novel HBV agents, and trial participation using in-depth interviews. Aim 2 will quantify priorities of PWH/PHBV and PHBV around these same trial elements through a national U.S. Survey. Aim 3 will develop ethical considerations and obtain feedback on provider- and patient- facing materials in collaboration with key stakeholders. Together, our three aims will clarify therapeutic advancement priorities and guide the ethical design of future innovative HBV clinical research with significant implications for population health. This work is directly relevant to the health of all americans, as IT addresses chronic disease management, CO-morbidities, and the reduction of long-term burdens on the healthcare system.

Subawards

Subrecipient Amount Awarded
Hepatitis B Foundation "HBF will participate in the development and review of data collection instruments (in-depth interview (IDI) guides and online survey) and will contribute its… $36,300

Quick answers

Who received award R21AI198128?

R21AI198128 was awarded to The Trustees Of The University Of Pennsylvania by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 6, 2026.

How much is award R21AI198128 worth?

$414,984 has been obligated on R21AI198128.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award